



EBV R-GENE®

REAL TIME PCR ASSAYS - ARGENE® TRANSPLANT RANGE

The power of true experience



PIONEERING DIAGNOSTICS



EBV R-GENE®

KEY FEATURES

- Ready-to-use reagents
- Complete qualitative and quantitative kit
- Validated on most relevant sample types
- Validated with the major extraction and amplification platforms
- Designed for low to high throughput analysis
- Same procedure for all the ARGENE® Transplant kits

CLINICAL CONTEXT^{1,2}

Epstein-Barr Virus (EBV) is a DNA virus, member of the Herpesviridae family. This is an ubiquitous virus with a seroprevalence reaching 95% in adult population. After primo-infection, usually asymptomatic, EBV enters in latency in B lymphocyte cells.

In transplant patients, the major complication linked to EBV infection is EBV-related Post-Transplant Lymphoproliferative Disorders (PTLD), recognized as a significant cause of morbidity and mortality^{1,2}. PTLT result from the uncontrolled proliferation of lymphoid cells. It can occur at any age and after all types of transplantation (Hematopoietic Stem Cells Transplantation (HSCT) and Solid Organ Transplantation (SOT)), but allogeneic-HSCT are at a particular risk for developing EBV-PTLD (overall incidence is 3.2%, with mortality around 30%)¹.



TECHNICAL INFORMATION

ORDERING INFORMATION	EBV R-GENE® - Ref. 69-002B
Type of kit	Real-time detection and quantification kit
Gene target	BXLF1 gene coding for thymidine kinase
Validated specimens	Whole blood, Plasma, CSF, BAL, Biopsies
Validated extraction platforms	EMAG®, easyMAG®, MagNA Pure Compact, MagNA Pure LC, QIAAsymphony SP, QIAamp DNA Blood Mini Kit, DNA Extraction kit (ref. 67-000)
Validated amplification platforms	LightCycler 2.0, LightCycler 480 (System II), ABI 7500, ABI 7500 Fast, ABI 7500 Fast Dx, ViiA 7, StepOne, Rotor-Gene Q, CFX96
Limit of Detection (LoD 95%)	Whole blood: 2.3 log ₁₀ copies/mL
Quantification Range	2.7 to 7.0 log ₁₀ copies/mL
Controls included	Extraction / Inhibition Control, Negative Control, Positive Control (QS3), 4 Quantification Standards, Sensitivity Control
Number of tests	90 tests
Storage conditions	-15°C / -31°C
Status	For <i>in vitro</i> diagnostic use, CE-IVD marking

OTHER ARGENE® TRANSPLANT KITS

- CMV R-GENE® (69-003B) • HSV1 HSV2 VZV R-GENE® (69-004B) • ADENOVIRUS R-GENE® (69-010B) • BK Virus R-GENE® (69-013B)
- Parvovirus B19 R-GENE® (69-019B) • CMV HHV6,7,8 R-GENE® (69-100B)

REFERENCES

1. Styczynski *et al.*, Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. *Haematologica* 2016; 101(7): 803-811
2. San-Juan *et al.*, Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. *Clin Microbiol Infect* 2014; 20 (7): 109-118